Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
  • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
  • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56983—Viruses
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
  • A61K2039/507—Comprising a combination of two or more separate antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/565—Complementarity determining region [CDR]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
  • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
  • G01N2333/08—RNA viruses
  • G01N2333/18—Togaviridae; Flaviviridae
  • G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2469/00—Immunoassays for the detection of microorganisms
  • G01N2469/10—Detection of antigens from microorganism in sample from host
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Virology (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Microbiology (AREA)
• Biomedical Technology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Biochemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Biotechnology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Cell Biology (AREA)
• Food Science & Technology (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Tropical Medicine & Parasitology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=57126199

Family Applications (2)

Family Applications Before (1)

Country Status (28)

Families Citing this family (11)

Family Cites Families (5)

• 2016
  • 2016-04-13 MA MA041517A patent/MA41517A/en unknown
  • 2016-04-14 EP EP16780715.5A patent/EP3283101A4/en active Pending
  • 2016-04-14 TW TW105111764A patent/TWI772257B/en active
  • 2016-04-14 CN CN202111464377.9A patent/CN114478756A/en active Pending
  • 2016-04-14 PE PE2022000095A patent/PE20220297A1/en unknown
  • 2016-04-14 WO PCT/US2016/027466 patent/WO2016168417A2/en active Application Filing
  • 2016-04-14 CA CA2982491A patent/CA2982491C/en active Active
  • 2016-04-14 CA CA3176525A patent/CA3176525A1/en active Pending
  • 2016-04-14 KR KR1020177032434A patent/KR102541905B1/en active IP Right Grant
  • 2016-04-14 US US15/566,283 patent/US10787503B2/en active Active
  • 2016-04-14 TN TNP/2017/000438A patent/TN2017000438A1/en unknown
  • 2016-04-14 UA UAA201711061A patent/UA125206C2/en unknown
  • 2016-04-14 MY MYPI2017703760A patent/MY191666A/en unknown
  • 2016-04-14 AU AU2016250188A patent/AU2016250188C1/en active Active
  • 2016-04-14 CN CN201680034592.6A patent/CN107708726B/en active Active
  • 2016-04-14 AR ARP160101021A patent/AR104264A1/en unknown
  • 2016-04-14 SG SG11201708152SA patent/SG11201708152SA/en unknown
  • 2016-04-14 CR CR20170518A patent/CR20170518A/en unknown
  • 2016-04-14 EA EA201792220A patent/EA037060B1/en unknown
  • 2016-04-14 PE PE2017002105A patent/PE20180171A1/en unknown
  • 2016-04-14 SG SG10202107295XA patent/SG10202107295XA/en unknown
  • 2016-04-14 TW TW111131757A patent/TW202248210A/en unknown
  • 2016-04-14 IL IL290449A patent/IL290449B2/en unknown
  • 2016-04-14 NZ NZ736445A patent/NZ736445A/en unknown
  • 2016-04-14 CR CR20210438A patent/CR20210438A/en unknown
  • 2016-04-14 JP JP2017553887A patent/JP6979875B2/en active Active
  • 2016-04-14 BR BR112017021952A patent/BR112017021952A2/en active Search and Examination
  • 2016-04-14 KR KR1020237018988A patent/KR20230087616A/en not_active Application Discontinuation
  • 2016-04-14 MX MX2017013286A patent/MX2017013286A/en unknown
• 2017
  • 2017-10-03 IL IL254891A patent/IL254891B/en unknown
  • 2017-10-10 DO DO2017000236A patent/DOP2017000236A/en unknown
  • 2017-10-10 CO CONC2017/0010316A patent/CO2017010316A2/en unknown
  • 2017-10-11 PH PH12017501865A patent/PH12017501865A1/en unknown
  • 2017-10-13 MX MX2021013207A patent/MX2021013207A/en unknown
  • 2017-10-13 CL CL2017002596A patent/CL2017002596A1/en unknown
  • 2017-11-14 EC ECIEPI201775750A patent/ECSP17075750A/en unknown
• 2018
  • 2018-05-15 HK HK18106245.0A patent/HK1246671A1/en unknown
• 2019
  • 2019-10-10 US US16/598,380 patent/US11345743B2/en active Active
• 2021
  • 2021-06-01 JP JP2021092090A patent/JP2021144047A/en active Pending
• 2022
  • 2022-04-28 AU AU2022202819A patent/AU2022202819A1/en active Pending
  • 2022-08-31 JP JP2022137389A patent/JP2022174144A/en active Pending

Also Published As

Similar Documents